Parkinson disease drug screening based on the interaction between D2 dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis  

作　　者：Zheng Zhou Jun-Ming Liao Peng Zhang Jun-Bao Fan Jie Chen Yi Liang 

机构地区：[1]State Key Laboratory of Virology,College of Life Sciences,Wuhan University,Wuhan 430072,China

出　　处：《Protein & Cell》2011年第11期899-905,共7页蛋白质与细胞（英文版）

基　　金：by the National Key Basic Research Foundation of China(Grant No.2006CB910301);the National Programs for High Technology Research and Development Program(863 Program)(No.2004AA404260);the National Natural Science Foundation of China(Grant Nos.30970599 and 30770421);the Fundamental Research Funds for the Central Universities of China(Grant No.1104006).

摘　　要：Parkinson’s disease is the second most common neurodegenerative disease in the world.Beta-arrestin-2 has been reported to be an important protein involved in D2 dopamine receptor desensitization,which is essential to Parkinson’s disease.Moreover,the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson’s disease has recently been shown.We studied the interaction between D2 dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis.The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D2 dopamine receptor interaction among them.These compounds are promising therapies for Parkinson’s disease,and the method used in this study has great potential for application in large-scale drug screening and evaluation.

关 键 词：drug screening D2 dopamine receptor beta-arrestin-2 capillary zone electrophoresis proteinprotein interaction Parkinson’s disease 

分 类 号：R74[医药卫生—神经病学与精神病学]